Studies from National Taiwan University Hospital and School of Medicine Reveal New Findings on Type 2 Diabetes (The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 …): Nutritional and Metabolic Diseases and Conditions – Type 2 Diabetes

Disease Prevention Daily

2022 DEC 09 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Investigators publish new report on type 2 diabetes. According to news reporting from Taipei, Taiwan, by NewsRx journalists, research stated, “Whether metformin might reduce the risk of multiple myeloma (MM) has not been extensively researched in humans. The study subjects were enrolled from the reimbursement database of Taiwan’s National Health Insurance.”

Funders for this research include Ministry of Science And Technology.

Our news editors obtained a quote from the research from National Taiwan University Hospital and School of Medicine: “A total of 739,553 patients who had a new diagnosis of type 2 diabetes mellitus during 1999-2009 were identified. They were categorized as metformin initiators (metformin (+)) and non-metformin initiators (metformin (-)) based on the prescriptions of antidiabetic drugs that included metformin and did not include metformin within the initial 12 months, respectively. MM incidence was calculated after the initial 12 months of treatment group assignment until 31 December 2011. Hazard ratios based on intention-to-treat (ITT) and per-protocol (PP) approaches were estimated by Cox regression weighted by propensity scores. In the ITT analyses, the respective incidence rates for 497,248 metformin (+) and 242,305 metformin (-) were 9.97 and 14.33 per 100,000 person-years. The hazard ratio that compared metformin (+) to metformin (-) in the ITT analysis was 0.710 (95% confidence interval 0.593-0.850). In the PP analysis, the respective incidence rates were 5.14 and 13.98 per 100,000 person-years, and the hazard ratio was 0.355 (95% confidence interval, 0.270-0.466). The lower risk of MM among metformin (+) was supported by subgroup and sensitivity analyses.”

According to the news editors, the research concluded: “Type 2 diabetes patients who are initiated with metformin treatment have a significantly lower risk of MM, especially when they adhere to metformin treatment.”

For more information on this research see: The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 Diabetes Mellitus. Cancers, 2022,14(5637):5637. (Cancers - http://www.mdpi.com/journal/cancers/). The publisher for Cancers is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/cancers14225637.

Our news journalists report that additional information may be obtained by contacting Chin-Hsiao Tseng, Department of Internal Medicine, National Taiwan University Hospital and School of Medicine, Taipei 10051, Taiwan.